Lava Therapeutics Nv (LVTX)
$2.64
Market is closed - opens 7 PM, 26 Apr 2024
Insights on Lava Therapeutics Nv
Increasing Revenue
Revenue is up for the last 2 quarters, 53.0K → 352.99K (in $), with an average increase of 85.0% per quarter
Increasing Net Profit
Netprofit is up for the last 5 quarters, -14.99M → -6.49M (in $), with an average increase of 24.3% per quarter
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 239.5% return, outperforming this stock by 317.2%
Performance
- $2.55$2.85$2.64
3.41%
Downside
Day's Volatility :10.53%
Upside
7.37%
- $1.13$6.47$2.64
57.2%
Downside
52 Weeks Volatility :82.53%
Upside
59.2%
Returns
| Period | Lava Therapeutics Nv | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 44.26% | 0.5% | 0.0% |
6 Months | 111.2% | 11.7% | 0.0% |
1 Year | 74.83% | 6.2% | 2.2% |
3 Years | -77.72% | 13.5% | -23.0% |
Highlights
Market Capitalization | 70.2M |
Book Value | $1.95 |
Earnings Per Share (EPS) | -1.57 |
Wall Street Target Price | 6.8 |
Profit Margin | 0.0% |
Operating Margin TTM | -1541.64% |
Return On Assets TTM | -22.06% |
Return On Equity TTM | -61.18% |
Revenue TTM | 6.8M |
Revenue Per Share TTM | 0.25 |
Quarterly Revenue Growth YOY | -86.6% |
Gross Profit TTM | -20.7M |
EBITDA | -42.6M |
Diluted Eps TTM | -1.57 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.51 |
EPS Estimate Next Year | -2.19 |
EPS Estimate Current Quarter | -0.12 |
EPS Estimate Next Quarter | -0.42 |
Analyst Recommendation
Buy
90%Buy
9%Hold
0
0%Sell
Based on 11 Wall street analysts offering stock ratings for Lava Therapeutics Nv(by analysts ranked 0 to 5 stars)
Based on 11 analyst
- Current
- 1M Ago
- 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00
Analyst Forecast
What analysts predicted
Upside of 157.58%
Current $2.64
Target $6.80
Technicals Summary
Sell
Neutral
Buy
Lava Therapeutics Nv is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Lava Therapeutics Nv | -34.49% | 111.2% | 74.83% | -77.72% | -81.54% |
 Moderna, Inc. | -1.15% | 39.75% | -18.77% | -40.22% | 304.34% |
 Regeneron Pharmaceuticals, Inc. | -7.56% | 12.46% | 14.48% | 77.72% | 159.17% |
 Novo Nordisk A/s | -2.8% | 32.13% | 52.48% | 239.51% | 414.16% |
 Vertex Pharmaceuticals Incorporated | -4.96% | 10.08% | 23.01% | 83.3% | 130.08% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Lava Therapeutics Nv | 0.25 | NA | NA | -1.51 | -0.61 | -0.22 | NA | 1.95 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Lava Therapeutics Nv | Buy | $70.2M | -81.54% | 0.25 | 0.0% |
Moderna, Inc. | Buy | $41.7B | 304.34% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 159.17% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 414.16% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 130.08% | 28.81 | 36.68% |
Institutional Holdings
PNC Financial Services Group Inc
0.25%Pathway Financial Advisors LLC
0.05%
Company Information
Organization | Lava Therapeutics Nv |
Employees | 37 |
CEO | Mr. Stephen Allen Hurly M.B.A., M.Sc. |
Industry | Services |
